Biotec Pharmacon - Mandatory notification of trade

(Tromsø 26. June 2017) Rolf E. Engstad, CSO of Biotec BetaGlucans has on 23.
June purchased 20 000 shares in Biotec Pharmacon at NOK 5.50 per share. After
this transaction holds Engstad 370.774 shares and 80.000 options in Biotec
Pharmacon
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact

Børge Sørvoll
CFO
+47 952 90 187
borge.sorvoll@biotec.no